<table id="L19e32cd7-1529-499e-a86b-9ff58dc7c223" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 2. Complete Responders at 3-Month Post-Treatment for Different  Baseline AK Lesion Counts</caption>
<colgroup>
<col width="29%"></col>
<col width="20%"></col>
<col width="18%"></col>
<col width="18%"></col>
<col width="14%"></col>
</colgroup>
<thead>
<tr><td></td><td align="center" colspan="2">Australian Study<br/></td><td align="center" colspan="2"> U.S. Study<br/></td></tr>
<tr><td>Baseline Lesion Count</td><td align="center">
												Metvixia-PDT</td><td align="center">Vehicle PDT</td><td align="center">
												Metvixia-PDT</td><td align="center">Vehicle PDT</td></tr>
</thead>
<tbody>
<tr><td>Below 4</td><td align="center">49/55 (89%)</td><td align="center">3/15 (20%)</td><td align="center">N/A</td><td align="center">N/A</td></tr>
<tr><td>4 â€“ 10 </td><td align="center">18/27 (67%)</td><td align="center">0/7</td><td align="center">33/42 (79%)</td><td align="center">8/38 (21%)</td></tr>
<tr><td>More than 10</td><td align="center">4/6 (67%)</td><td align="center">0/1</td><td align="center">N/A</td><td align="center">N/A</td></tr>
<tr><td>				Total</td><td align="center">
												71/88 (81%)</td><td align="center">
												3/23 (13%)</td><td align="center">
												33/42 (79%)</td><td align="center">
												8/38 (21%)</td></tr>
</tbody>
</table>